NeuroPace (NPCE) Non-Current Deffered Revenue (2020 - 2021)
NeuroPace (NPCE) posted quarterly Non-Current Deffered Revenue of $1.4 million for Q4 2021, up 7.61% year-over-year from $1.3 million in Q4 2020, and up 34.49% quarter-over-quarter from $1.0 million in Q3 2021.
NeuroPace (NPCE) Non-Current Deffered Revenue (2020 - 2021) Analysis & Trends
NeuroPace's Non-Current Deffered Revenue history runs 2 years deep, the most recent figure standing at $1.4 million for Q4 2021.
- In Q4 2021, Non-Current Deffered Revenue rose 7.61% year-over-year to $1.4 million; the TTM figure through Dec 2021 stood at $1.4 million (up 7.61% YoY), while the FY2021 annual figure was $1.4 million, up 7.61% from the prior year.
- Non-Current Deffered Revenue for Q4 2021 stood at $1.4 million, up from $1.0 million in the prior quarter.
- The five-year high for Non-Current Deffered Revenue was $1.4 million in Q4 2021, with the low at $1.0 million in Q3 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 202.72 Bn | 197.12 Bn | 7.27 Bn | - |
| 2 | Stryker | 126.42 Bn | 122.94 Bn | 4.50 Bn | - |
| 3 | Medtronic | 119.75 Bn | 110.53 Bn | 6.41 Bn | - |
| 4 | Boston Scientific | 74.13 Bn | 73.60 Bn | 3.85 Bn | - |
| 5 | Edwards Lifesciences | 51.78 Bn | 47.53 Bn | 1.35 Bn | - |
| 6 | Dexcom | 35.29 Bn | 33.34 Bn | 830.00 Mn | - |
| 7 | GE HealthCare Technologies | 33.95 Bn | 31.85 Bn | 2.18 Bn | - |
| 8 | Koninklijke Philips | 26.22 Bn | 22.90 Bn | 4.55 Bn | 539.34 Mn |
| 9 | Steris | 23.21 Bn | 22.73 Bn | 684.20 Mn | - |
| 10 | NeuroPace | 478.49 Mn | 426.79 Mn | 18.91 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | 1.40 Mn |
| Sep 30, 2021 | 1.04 Mn |
| Jun 30, 2021 | 1.09 Mn |
| Mar 31, 2021 | 1.20 Mn |
| Dec 31, 2020 | 1.30 Mn |